Literature DB >> 26718572

Eculizumab-related progressive multifocal leukoencephalopathy.

Emilio Gómez-Cibeira1, Yerko Ivanovic-Barbeito1, Eduardo Gutiérrez-Martínez1, Enrique Morales1, Manuel Abradelo1, Amaya Hilario1, Ana Ramos1, Juan Ruiz-Morales1, Alberto Villarejo-Galende2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26718572      PMCID： PMC4776092          DOI： 10.1212/WNL.0000000000002312

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

Review 1.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

2.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 4.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

5.  Eculizumab for paroxysmal nocturnal haemoglobinuria.

Authors:  Charles Parker
Journal:  Lancet       Date:  2009-01-12       Impact factor: 79.321

6.  Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Daniel Pelletier; Diego Cadavid; Achim Gass; Nancy D Richert; Ernst-Wilhelm Radue; Massimo Filippi
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

Review 7.  Complement and viral pathogenesis.

Authors:  Kristina A Stoermer; Thomas E Morrison
Journal:  Virology       Date:  2011-02-02       Impact factor: 3.616
  7 in total
  4 in total

Review 1.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

Review 2.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

3.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

4.  Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Toru Kawakami; Hideyuki Nakazawa; Yukifumi Kurasawa; Hitoshi Sakai; Sayaka Nishina; Noriko Senoo; Yasushi Senoo; Fumihiro Ishida
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.